Wyeth, Schering broker fees probe
This article was originally published in The Tan Sheet
Executive Summary
Justice Department antitrust investigators are looking into same-day move by Wyeth and Schering-Plough to reduce fees paid to at least one firm, Compass Marketing, which distributes consumer products to "alternative" outlets such as convenience stores. Both companies reduced fees from 4% to 3% on March 30. Sykesville, Md.-based Compass is cooperating with DoJ requests for documents and employee interviews; it was asked for information about only those two companies. Firm says it was fired by Wyeth Aug. 9. DoJ declined to say whether investigators are looking into other consumer products companies or brokers...
You may also be interested in...
Schering, Wyeth Named In Price-Fixing Suit By Contract Broker
Schering-Plough and Wyeth are accused of fixing prices in distribution contracts involving the firms' OTC drugs in a lawsuit filed in Greenbelt, Md. federal court May 26
Wyeth DoJ probe
Firm "expects to receive a subpoena in the near future" for Department of Justice inquiry "into allegations of collusive practices" with another drug company, Wyeth states in Feb. 11 SEC filing. Case has been referred to a grand jury, Wyeth says. Allegations refer to collusion "relating to commission rates for a sales broker for a small segment of the" firm's OTC business, filing notes, although Wyeth maintains "our practices regarding brokers have not violated the antitrust laws." Schering-Plough disclosed a similar investigation in November. DoJ initiated the inquiry following same-day move by the two firms to reduce fees to Compass Marketing (1"The Tan Sheet" Aug. 19, 2002, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”